Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Bibliographic record

Once-weekly semaglutide in adults with overweight or obesity

Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S…. New England Journal of Medicine 2021

Document identifier
CEI-BR-123
Series
Bibliographic record
Version
1.0
Published
30 Jul 2026
Last reviewed
30 Jul 2026
Certainty
Not rated

§1Bibliographic record

§1.1Record

Authors
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF
Title
Once-weekly semaglutide in adults with overweight or obesity
Source
New England Journal of Medicine
Year
2021
Volume, issue, pages
384(11):989–1002
Digital object identifier
10.1056/NEJMoa2032183
PubMed identifier
33567185
Record type
Journal article
Institute identifier
CEI-BR-123

§1.2Institute documents citing this record

Table 1. Documents in the Institute set that cite this record.

DocumentSeries
Monograph: SemaglutideCompound monograph
Monograph: CagriSema (cagrilintide with semaglutide)Compound monograph
Monograph: AmycretinCompound monograph
Trial abstract: STEP-1Trial abstract
Synthesis: Glucagon-like peptide-1 receptor agonists for weight reduction in…Evidence synthesis
Synthesis: Dual and triple incretin receptor agonists compared with single…Evidence synthesis
Synthesis: Gastrointestinal adverse events with incretin receptor agonistsEvidence synthesis
Synthesis: Semaglutide in obesity and overweight in adults: effect on the anchor…Evidence synthesis
Synthesis: Semaglutide in type 2 diabetes mellitus: effect on the anchor outcomeEvidence synthesis
Synthesis: CagriSema (cagrilintide with semaglutide) in obesity and overweight…Evidence synthesis
Synthesis: CagriSema (cagrilintide with semaglutide) in type 2 diabetes…Evidence synthesis
Synthesis: Semaglutide in atherosclerotic cardiovascular disease and…Evidence synthesis
Synthesis: Semaglutide in heart failure with preserved ejection fraction and…Evidence synthesis
Synthesis: Semaglutide in obesity and overweight in adults: tolerability and…Evidence synthesis
Synthesis: Semaglutide in type 2 diabetes mellitus: tolerability and…Evidence synthesis
Synthesis: CagriSema (cagrilintide with semaglutide) in obesity and overweight…Evidence synthesis
Synthesis: CagriSema (cagrilintide with semaglutide) in type 2 diabetes…Evidence synthesis
Synthesis: Semaglutide in atherosclerotic cardiovascular disease and…Evidence synthesis
Synthesis: Semaglutide in heart failure with preserved ejection fraction and…Evidence synthesis
Synthesis: Semaglutide in obesity and overweight in adults: durability of effectEvidence synthesis
Synthesis: Semaglutide in type 2 diabetes mellitus: durability of effectEvidence synthesis
Synthesis: CagriSema (cagrilintide with semaglutide) in obesity and overweight…Evidence synthesis
Synthesis: CagriSema (cagrilintide with semaglutide) in type 2 diabetes…Evidence synthesis
23 citing documents.

§1.3Subject tags

semaglutide obesity STEP

Compound Evidence Institute · CEI-BR-123 · https://compoundevidence.com/bibliography/wilding2021/ · retrieved 30 July 2026
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.